Proteoglycan 4 ( PRG4 ) treatment improves skin wound healing in a porcine model
The FASEB Journal · 2024
DOI: 10.1096/fj.202301289rrr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Nicoletta Ninkovic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Proteoglycans, Cartilage, Articular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Government | Natural Sciences and Engineering Research Council of Canada (NSERC), Lubris Biopharma LLC, Natural Sciences and Engineering Research Council of Canada.
Themen: Wundversorgung
Abstract (Originalsprache)
Proteoglycan 4 (PRG4) is a boundary lubricant originally identified in articular cartilage and has been since shown to have immunomodulation and antifibrotic properties. Previously, we have demonstrated that recombinant human (rh)PRG4 treatment accelerates auricular cartilage injury closure through an inhibition of the fibrotic response, and promotion of tissue regeneration in mice. The purpose of the current study was to examine the effects of rhPRG4 treatment (vs. a DMSO carried control) on full‐thickness skin wound healing in a preclinical porcine model. Our findings suggest that while rhPRG4 did not significantly accelerate nor impede full‐thickness skin wound closure, it did improve repair quality by decreasing molecular markers of fibrosis and increasing re‐vascularization. We also demonstrated that rhPRG4 treatment increased dermal adipose tissue during the healing process specifically by retaining adipocytes in the wound area but did not inhibit lipolysis. Overall, the results of the current study have demonstrated that rhPRG4 acts as antifibrotic agent and regulates dermal adipose tissue during the healing processes resulting in a tissue with a trajectory that more resembles the native skin vs. a fibrotic patch. This study provides strong rationale to examine if rhPRG4 can improve regeneration in human wounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
- McCaig Institute for Bone & Joint Health, University of Calgary, Calgary, Alberta, Canada.
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.
- Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
- Department of Biomedical Engineering, University of Calgary, Calgary, Alberta, Canada.
- Department Cell Biology and Anatomy, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Nicoletta Ninkovic, Holly D Sparks, Dragana Ponjevic, Greg Muench, Jeff A Biernaskie, Roman J Krawetz
Förderung
- Canadian Government | Natural Sciences and Engineering Research Council of Canada (NSERC)
- Lubris Biopharma LLC
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Ninkovic, N., Sparks, H. D., Ponjevic, D., Muench, G., Biernaskie, J. A., & Krawetz, R. J. (2024). Proteoglycan 4 ( PRG4 ) treatment improves skin wound healing in a porcine model. The FASEB Journal. https://doi.org/10.1096/fj.202301289rrr
Vancouver
Ninkovic N, Sparks HD, Ponjevic D, Muench G, Biernaskie JA, Krawetz RJ. Proteoglycan 4 ( PRG4 ) treatment improves skin wound healing in a porcine model. The FASEB Journal. 2024. doi:10.1096/fj.202301289rrr
BibTeX
@article{Ninkovic2024,
author = {Ninkovic, Nicoletta and Sparks, Holly D and Ponjevic, Dragana and Muench, Greg and Biernaskie, Jeff A and Krawetz, Roman J},
title = {Proteoglycan 4 ( PRG4 ) treatment improves skin wound healing in a porcine model},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202301289rrr}
}
EUVIMED